Philip Weidner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6932677/publications.pdf

Version: 2024-02-01

1684188 1588992 10 102 5 8 citations g-index h-index papers 10 10 10 209 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Nivolumab plus ipilimumab in second-line combination therapy for older patients with esophageal squamous cell cancer (AIO-STO-0117 trial) Journal of Clinical Oncology, 2022, 40, 303-303.	1.6	1
2	Abstract 4018: Long-term response to Trastuzumab in patients with advanced gastric or gastroesophageal adenocarcinoma - A retrospective study. Cancer Research, 2022, 82, 4018-4018.	0.9	0
3	PPARÎ ³ induces PD-L1 expression in MSS+ colorectal cancer cells. Oncolmmunology, 2021, 10, 1906500.	4.6	15
4	Pancreatic Acinar Cell Carcinoma with Germline BRCA2 Mutation and Severe Pancreatic Panniculitis: A Case Report. Visceral Medicine, 2021, 37, 447-450.	1.3	3
5	Expression of the EGFR-RAS Inhibitory Proteins DOK1 and MTMR7 and its Significance in Colorectal Adenoma and Adenoma Recurrence. Journal of Gastrointestinal and Liver Diseases, 2021, 30, 446-455.	0.9	3
6	Myotubularin-related protein 7 activates peroxisome proliferator-activated receptor-gamma. Oncogenesis, 2020, 9, 59.	4.9	6
7	Docking protein-1 promotes inflammatory macrophage signaling in gastric cancer. Oncolmmunology, 2019, 8, e1649961.	4.6	14
8	Impact of Direct Acting Antiviral (DAA) Treatment on Glucose Metabolism and Reduction of Pre-diabetes in Patients with Chronic Hepatitis C. Journal of Gastrointestinal and Liver Diseases, 2019, 27, 281-289.	0.9	27
9	PPARÎ 3 -activation increases intestinal M1 macrophages and mitigates formation of serrated adenomas in mutant <i>KRAS</i> mice. Oncolmmunology, 2018, 7, e1423168.	4.6	12
10	Myotubularin-related protein 7 inhibits insulin signaling in colorectal cancer. Oncotarget, 2016, 7, 50490-50506.	1.8	21